{"nctId":"NCT05523297","briefTitle":"Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery","startDateStruct":{"date":"2022-11-30","type":"ACTUAL"},"conditions":["Bleeding Cardiac Surgery Patients"],"count":420,"armGroups":[{"label":"Octaplex","type":"EXPERIMENTAL","interventionNames":["Drug: Octaplex"]},{"label":"Frozen plasma","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Frozen Plasma Product, Human"]}],"interventions":[{"name":"Octaplex","otherNames":[]},{"name":"Frozen Plasma Product, Human","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adult (≥18 years old) patients undergoing any index cardiac surgery employing CPB\n2. Coagulation factor replacement with PCC or FP ordered in the operating room for:\n\n   1. Management of bleeding, or\n   2. Anticipated bleeding in a patient who has been on-pump for \\>2 hours or has undergone a complex procedure (e.g., aortocoronary bypass \\[ACB\\] plus aortic valve replacement)\n3. Coagulation factor deficiency, either known to exist (e.g., as indicated by elevated EXTEM clotting time \\[CT\\] or INR) or suspected based on the clinical situation\n4. Patients who have given written informed consent. In United States patients will provide informed consent prior to surgery. In Canada, informed consent will be obtained after surgery, in accordance with Article 3.7A of the 2018 Tri- Council Policy Statement on the Ethical Conduct for Research Involving Humans.\n\nExclusion Criteria:\n\n1. Undergoing heart transplantation, insertion or removal of ventricular assist devices (not including intra-aortic balloon pump \\[IABP\\]) or repair of thoracoabdominal aneurysm\n2. Critical state immediately before surgery with high probability of death within 24 hours of surgery (e.g., acute aortic dissection, cardiac arrest within 24 hours before surgery)\n3. Severe right heart failure (clinical diagnosis ± echocardiography)\n4. Known contraindications to heparin\n5. PCC required for reversal of warfarin or direct oral anticoagulant (DOAC; dabigatran, rivaroxaban, apixaban or edoxaban) within 3 days prior to or during surgery\n6. Known thromboembolic event (TEE) within 3 months prior to surgery\n7. History of severe allergic reactions to PCC or FP\n8. Individuals who have immunoglobulin A (IgA) deficiency with known antibodies against IgA\n9. Refusal of allogeneic blood products\n10. Known pregnancy\n11. Currently enrolled in other interventional clinical trials","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Requiring Additional Hemostatic Intervention","description":"Defined as 'effective' if no additional hemostatic intervention, such as administration of any systemic hemostatic agents (including platelets, cryoprecipitate, fibrinogen concentrate, activated recombinant factor VII \\[rFVIIa\\], other coagulation factor products or a second dose of IMP) or any hemostatic interventions (including surgical re-opening for bleeding) is required from 60 minutes to 24 hours after initiation of the first dose of IMP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"125","spread":null}]},{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Global Hemostatic Response Based on Requirement of Additional Hemostatic Intervention and Decreased Hemoglobin Levels","description":"Defined as 'positive' if no additional hemostatic intervention is required and hemoglobin levels decrease by \\<30% (after accounting for red cell transfusions) from 60 minutes to 24 hours after initiation of the first dose of IMP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"83","spread":null}]},{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the Amount of Chest Tube Drainage Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"471.20","spread":"358.32"},{"groupId":"OG001","value":"641.90","spread":"465.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"690.90","spread":"465.62"},{"groupId":"OG001","value":"922.90","spread":"631.90"}]}]}]},{"type":"SECONDARY","title":"Compare the Incidence of Severe to Massive Bleeding Between the Octaplex and FP Groups Using a Modification of the Universal Definition of Perioperative Bleeding (UDPB).","description":"Yes or no refers to whether severe to massive bleeding was present.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"136","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"129","spread":null}]},{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"136","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Efficacy in Terms of the Mean Number of Total Allogeneic Blood Products (ABPs) (IMP and Non-IMP) Transfused Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":"6.95"},{"groupId":"OG001","value":"13.79","spread":"11.42"}]}]}]},{"type":"SECONDARY","title":"Compare Efficacy in Terms of the Mean Number of Total Non-IMP Allogeneic Blood Products Transfused Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":"6.95"},{"groupId":"OG001","value":"9.33","spread":"10.64"}]}]}]},{"type":"SECONDARY","title":"Compare Efficacy in Terms of the Mean Number of Total Non-IMP Allogeneic Blood Components Transfused Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":"6.25"},{"groupId":"OG001","value":"6.73","spread":"10.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":"8.43"},{"groupId":"OG001","value":"8.87","spread":"16.04"}]}]}]},{"type":"SECONDARY","title":"Compare Mean Number of Individual Allogeneic Blood Components Transfused Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.12"},{"groupId":"OG001","value":"4.70","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.12"},{"groupId":"OG001","value":"0.23","spread":"1.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"1.72"},{"groupId":"OG001","value":"2.02","spread":"2.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"4.50"},{"groupId":"OG001","value":"4.48","spread":"6.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.42"},{"groupId":"OG001","value":"0.14","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"1.273"},{"groupId":"OG001","value":"7.25","spread":"34.818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"1.273"},{"groupId":"OG001","value":"2.78","spread":"34.792"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.378"},{"groupId":"OG001","value":"2.9","spread":"3.466"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":"5.827"},{"groupId":"OG001","value":"5.6","spread":"11.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.421"},{"groupId":"OG001","value":"0.16","spread":"0.765"}]}]}]},{"type":"SECONDARY","title":"Compare Efficacy in Terms of the Incidence of Transfusion of Individual Allogeneic Blood Components Transfused Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"200","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"75","spread":null}]},{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"99","spread":null}]},{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"195","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"56","spread":null}]},{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"195","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"53","spread":null}]},{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"97","spread":null}]},{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"195","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Incidence of Administration of Non-IMP Coagulation Factor Products Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"159","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"197","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"190","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"148","spread":null}]},{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"156","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"197","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"190","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"145","spread":null}]},{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Incidence of Intracerebral Hemorrhage Between the Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Incidence of Gastrointestinal Hemorrhage Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Incidence of Surgical Re-exploration Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"189","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"187","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"187","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in International Normalised Ratio (INR) Before and After Therapy Administration.","description":"The international normalized ratio (INR) is a standardized measure of prothrombin time (PT), ensuring consistency in results across different laboratories. The normal range for INR is around 0.8 to 1.2. Higher INR values indicate a slower clotting time and are associated with bleeding. Effective procoagulant therapy can reduce/normalize the INR.\n\nINR reduction was considered successful if the magnitude of the reduction was \\>1.0 or the post-treatment level dropped below 1.5 (INR \\>1.5 indicates that one or more coagulation factor levels are below the 30% critical threshold)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.76"},{"groupId":"OG001","value":"-0.7","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in Prothrombin Time (PT)","description":"The prothrombin time (PT) measures the time it takes for clotting to occur, primarily assessing the extrinsic pathway of the coagulation cascade. Normal PT values range from 9 to 13 seconds. Higher PT values indicate a prolonged clotting time, suggesting potential issues with clotting factors such as fibrinogen, factors V, VII, and X and prothrombin, and are associated with bleeding. Effective procoagulant therapy can reduce/normalize the PT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"20.90"},{"groupId":"OG001","value":"-0.7","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in Activated Partial Thromboplastin Time (aPTT)","description":"Activated partial thromboplastin time (aPTT) is a standard laboratory test that measures how long it takes (in seconds) for clotting to occur (in the presence of an activator). It evaluates the intrinsic and common pathways of the coagulation cascade, assessing factors such as VIII, IX, XI, and XII, as well as fibrinogen. Prolonged aPTT may signify deficiencies in these clotting factors and is associated with bleeding. Effective procoagulant therapy can shorten/normalize the aPTT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.5","spread":"121.47"},{"groupId":"OG001","value":"-45.6","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in Fibrinogen Activity","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.07"},{"groupId":"OG001","value":"0.5","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in ROTEM EXTEM CT","description":"A rotational thromboelastometry (ROTEM; Werfen) device can be used at the bedside to rapidly assess the patient's coagulation status. Different viscoelastic tests can be performed to assess the dynamics of clot formation and lysis. Specifically, the EXTEM test is activated with tissue factor and evaluates the extrinsic coagulation pathway, with clotting time (CT) providing a measure (in seconds) of how quickly a clot starts forming. Prolonged EXTEM CT is associated with bleeding. Effective procoagulant therapy can reduce/normalize the EXTEM CT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":"18.00"},{"groupId":"OG001","value":"-21.7","spread":"18.65"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in ROTEM EXTEM MCF","description":"A rotational thromboelastometry (ROTEM; Werfen) device can be used at the bedside to rapidly assess the patient's coagulation status. Different viscoelastic tests can be performed to assess the dynamics of clot formation and lysis. Specifically, the EXTEM test is activated with tissue factor and evaluates the extrinsic coagulation pathway, with maximum clot firmness (MCF) providing a measure (in mm) of the strength of the clot. Reduced EXTEM MCF is associated with bleeding. Effective procoagulant therapy can increase/normalize the EXTEM MCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"4.95"},{"groupId":"OG001","value":"6.7","spread":"9.54"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in ROTEM FIBTEM MCF","description":"A rotational thromboelastometry (ROTEM; Werfen) device can be used at the bedside to rapidly assess the patient's coagulation status. Different viscoelastic tests can be performed to assess the dynamics of clot formation and lysis. Specifically, the FIBTEM test evaluates fibrin-based clotting - it is extrinsically activated with tissue factor and additionally incorporates an inhibitor to eliminate the contribution of platelets to clotting. Maximum clot firmness (MCF) in the FIBTEM test provides a measure (in mm) of the strength of the fibrin-based clot. Reduced FIBTEM MCF is associated with bleeding. Effective procoagulant therapy to restore fibrinogen can increase/normalize the FIBTEM MCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.75"},{"groupId":"OG001","value":"1.4","spread":"13.78"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in Platelet Count Measured by Plateletworks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"22.97"},{"groupId":"OG001","value":"10.9","spread":"38.29"}]}]}]},{"type":"SECONDARY","title":"Comparison of the Effect of Octaplex Versus FP Administration on the Change in Platelet Function Measured by Plateletworks","description":"The Plateletworks device (Helena Laboratories) enables rapid bedside screening of platelet function. The system uses an impedance cell counter and Plateletworks reagent tubes to evaluate platelet function and monitor treatment effects. By comparing a baseline total platelet count against the platelet count measured in the presence of an agonist used to stimulate platelet aggregation (ADP, collagen, or arachidonic acid), the tests determine the percent aggregation or inhibition of functional platelets. Manufacturer reference ranges, determined by testing blood samples from healthy volunteers, are 86-100% for ADP, 70-100% for collagen, and 60-100% for arachidonic acid. Values within these ranges indicate 'normal (positive)' platelet aggregation, which is important for clotting; lower values may be considered 'abnormal (negative)' and reflective of platelet inhibition. The manufacturer advises each laboratory to establish their own reference ranges for their patient population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"10.34"},{"groupId":"OG001","value":"-18.2","spread":"17.72"}]}]}]},{"type":"SECONDARY","title":"Comparison of Total Time Elapsed From Initiation of the First Dose of IMP to Arrival Into the ICU Between the Octaplex and FP Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Incidence of Serious Treatment-emergent Adverse Events Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Duration of Mechanical Ventilation Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Duration of ICU Stay Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Duration of Hospitalization Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Incidence of Death Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Number of Days Alive and Out of Hospital Between Octaplex and FP Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"21.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":77,"n":213},"commonTop":["Atrial fibrillation","Anemia","Hypervolemia","Pleural effusion","Edema peripheral"]}}}